Bruker (NASDAQ:BRKR) Given New $60.00 Price Target at Wells Fargo & Company

Bruker (NASDAQ:BRKR) had its target price decreased by Wells Fargo & Company from $75.00 to $60.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. Wells Fargo & Company‘s price objective indicates a potential upside of 65.49% from the company’s current price.

BRKR has been the subject of several other reports. Stifel Nicolaus reduced their price target on Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a research report on Friday, February 14th. Guggenheim reiterated a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Citigroup reduced their target price on shares of Bruker from $75.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, April 7th. Finally, Barclays lowered their target price on Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Bruker has a consensus rating of “Moderate Buy” and an average price target of $65.00.

Bruker Trading Down 3.9 %

BRKR stock traded down $1.49 during midday trading on Thursday, reaching $36.26. The company’s stock had a trading volume of 1,034,460 shares, compared to its average volume of 1,487,492. The firm has a market capitalization of $5.50 billion, a price-to-earnings ratio of 47.88, a PEG ratio of 2.16 and a beta of 1.18. Bruker has a 1 year low of $34.10 and a 1 year high of $84.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The stock has a fifty day simple moving average of $45.10 and a two-hundred day simple moving average of $54.20.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, equities research analysts predict that Bruker will post 2.69 EPS for the current year.

Institutional Trading of Bruker

A number of hedge funds and other institutional investors have recently bought and sold shares of BRKR. Eagle Bay Advisors LLC raised its holdings in Bruker by 2,324.1% during the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after purchasing an additional 674 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in Bruker by 274.9% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 800 shares in the last quarter. Fifth Third Bancorp boosted its position in shares of Bruker by 54.2% in the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 390 shares during the period. UMB Bank n.a. increased its position in Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock worth $53,000 after buying an additional 248 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in shares of Bruker by 47.5% in the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after acquiring an additional 412 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.